TET2 and acute myeloid leukemia: Subsequent refinement of the AML genomic landscape has revealed a plethora of somatically mutated genes, including TET2, which has been associated with poor outcome following treatment with standard anthracycline and nucleoside analog-based chemotherapy (1, 6).